BRPI0608254A2 - anticorpos kim-1 para o tratamento de condições mediadas por th2 - Google Patents

anticorpos kim-1 para o tratamento de condições mediadas por th2

Info

Publication number
BRPI0608254A2
BRPI0608254A2 BRPI0608254-8A BRPI0608254A BRPI0608254A2 BR PI0608254 A2 BRPI0608254 A2 BR PI0608254A2 BR PI0608254 A BRPI0608254 A BR PI0608254A BR PI0608254 A2 BRPI0608254 A2 BR PI0608254A2
Authority
BR
Brazil
Prior art keywords
kim
antibodies
treatment
mediated conditions
mediated
Prior art date
Application number
BRPI0608254-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul D Rennert
Patricia Mccoon
Veronique Bailly
Alexey Lugovskoy
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BRPI0608254A2 publication Critical patent/BRPI0608254A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0608254-8A 2005-03-02 2006-03-02 anticorpos kim-1 para o tratamento de condições mediadas por th2 BRPI0608254A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65778905P 2005-03-02 2005-03-02
PCT/US2006/007441 WO2006094134A2 (en) 2005-03-02 2006-03-02 Kim-1 antibodies for treatment of th2-mediated conditions

Publications (1)

Publication Number Publication Date
BRPI0608254A2 true BRPI0608254A2 (pt) 2009-12-08

Family

ID=36648475

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608254-8A BRPI0608254A2 (pt) 2005-03-02 2006-03-02 anticorpos kim-1 para o tratamento de condições mediadas por th2

Country Status (14)

Country Link
US (2) US8206705B2 (cg-RX-API-DMAC7.html)
EP (2) EP1865985B1 (cg-RX-API-DMAC7.html)
JP (2) JP2008531719A (cg-RX-API-DMAC7.html)
KR (1) KR101213894B1 (cg-RX-API-DMAC7.html)
CN (2) CN101166542A (cg-RX-API-DMAC7.html)
AT (1) ATE478707T1 (cg-RX-API-DMAC7.html)
AU (2) AU2006218489B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0608254A2 (cg-RX-API-DMAC7.html)
CA (1) CA2599967C (cg-RX-API-DMAC7.html)
DE (1) DE602006016413D1 (cg-RX-API-DMAC7.html)
IL (1) IL185653A (cg-RX-API-DMAC7.html)
NZ (1) NZ562045A (cg-RX-API-DMAC7.html)
WO (1) WO2006094134A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708372B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064031A2 (en) * 2006-11-13 2008-05-29 Government Of The United States, As Represented Bythe Secretary Of The Department Of Health And Human Services Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses
CA2833785C (en) 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
MA43135A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes pour le du traitement du cancer
BR112018008390A2 (pt) 2015-10-30 2018-11-27 Aleta Biotherapeutics Inc composições e métodos para transdução tumoral

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6165733A (en) 1996-05-23 2000-12-26 Chiron Corporation γ II adaptin
CN1147584C (zh) 1996-05-24 2004-04-28 拜奥根有限公司 组织再生调节物
JP2001503271A (ja) 1996-11-01 2001-03-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒト粘膜アドレシン細胞接着分子―１（ＭＡｄＣＡＭ―１）およびそのスプライス変異体
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2274250A1 (en) 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1.beta. converting enzyme
CN101274962A (zh) 1998-01-23 2008-10-01 霍夫曼-拉罗奇有限公司 人il-12抗体
KR20010041765A (ko) 1998-03-11 2001-05-25 가마쿠라 아키오 ＩｇＥ 항체생산 억제제 및 자기면역질환 억제제
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
ATE425249T1 (de) 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
EP1401869B1 (en) * 2001-06-01 2007-12-26 Biogen Idec MA Inc. Molecules and methods for inhibiting shedding of kim-1
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US7553939B2 (en) 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
WO2003063792A2 (en) 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
US20050014687A1 (en) 2002-03-19 2005-01-20 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
DE60322744D1 (de) 2002-12-30 2008-09-18 Biogen Idec Inc Kim-1-antagonisten und verwendung zur immunsystemmodulation
EP3000886A1 (en) * 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
WO2005001092A2 (en) 2003-05-20 2005-01-06 Wyeth Compositions and methods for diagnosing and treating cancers
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
CA2560941A1 (en) 2004-03-24 2005-10-20 Telos Pharmaceuticals Llc Compositions as adjuvants to improve immune responses to vaccines and methods of use
US8025557B2 (en) 2009-02-27 2011-09-27 Illinois Tool Works Inc. Sanding clay

Also Published As

Publication number Publication date
WO2006094134A3 (en) 2006-10-19
HK1118007A1 (en) 2009-01-30
ATE478707T1 (de) 2010-09-15
CN101166542A (zh) 2008-04-23
DE602006016413D1 (de) 2010-10-07
IL185653A0 (en) 2008-01-06
KR101213894B1 (ko) 2012-12-20
EP2251037A1 (en) 2010-11-17
EP2251037B1 (en) 2015-01-14
KR20070110411A (ko) 2007-11-16
AU2011202405B2 (en) 2013-03-28
JP2012131825A (ja) 2012-07-12
CA2599967A1 (en) 2006-09-08
EP1865985A2 (en) 2007-12-19
US8206705B2 (en) 2012-06-26
AU2011202405A1 (en) 2011-06-09
WO2006094134A2 (en) 2006-09-08
EP1865985B1 (en) 2010-08-25
IL185653A (en) 2013-04-30
AU2006218489B2 (en) 2011-02-24
CN103751780A (zh) 2014-04-30
CA2599967C (en) 2014-10-21
US20100150905A1 (en) 2010-06-17
ZA200708372B (en) 2008-12-31
NZ562045A (en) 2010-12-24
AU2006218489A1 (en) 2006-09-08
JP2008531719A (ja) 2008-08-14
US20130089539A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
CR20130455A (es) Composiciones para el tratamiento de tumores
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
EP1954274A4 (en) SUBSTITUTED QUINOLONES AND METHODS OF USE
PT3415535T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
NL300936I2 (nl) Semaglutide
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
PT2061814E (pt) Anticorpos e imunoconjugados e suas utilizações
EP1850658A4 (en) IMPROVED PROCESS FOR THE TREATMENT OF DEGENERATIVE DISEASES OF RETINA
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
NL1028086A1 (nl) Sulfonamidederivaten voor de behandeling van ziekten.
NL1028087A1 (nl) Sulfonamiderivaten voor de behandeling van ziekten.
PT1924139E (pt) Métodos e aparelhos para reduzir o teor de proteína de agentes de diluição de espermatozoides
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
NL1033562A1 (nl) Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie.
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
BRPI0506723A (pt) métodos para o tratamento de distúrbios vasculares
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: BIOGEN MA INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), A61P 11/06 (2006.01), A61P 3